Summit Global Investments Acquires New Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Summit Global Investments bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,108 shares of the specialty pharmaceutical company’s stock, valued at approximately $232,000.

Other large investors have also bought and sold shares of the company. TD Private Client Wealth LLC grew its stake in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares during the period. Virtus Fund Advisers LLC bought a new position in Collegium Pharmaceutical during the third quarter worth about $72,000. KBC Group NV increased its stake in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares during the period.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares of the company’s stock, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 977 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the sale, the chief financial officer now owns 164,269 shares in the company, valued at $4,928,070. The trade was a 0.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,193 shares of company stock worth $3,243,594. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Down 1.3 %

Shares of NASDAQ:COLL opened at $30.15 on Wednesday. The firm has a fifty day moving average price of $30.57 and a two-hundred day moving average price of $32.54. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29. The company has a market cap of $949.30 million, a price-to-earnings ratio of 13.00 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on COLL shares. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Piper Sandler reduced their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.